Overview: Factor V Leiden Mutation Panel
Introduction: The Factor V Leiden Mutation Panel is a diagnostic tool designed to screen for thrombophilia using whole blood samples. In India, Factor V Leiden (FVL) mutation is the most common inherited thrombophilia (prevalence ~2-10 percent in certain communities), increasing VTE risk 5-8 fold, especially in pregnancy, surgery, or OCP use. High morbidity from under-testing in rural/low-SES patients with recurrent VTE or pregnancy loss, limited molecular labs, delayed anticoagulation leading to PE or stroke. Per molecular pathology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs PCR for FVL mutation over 1-2 days with high accuracy, valuable for risk stratification and family counseling. This diagnostic falls under thrombophilia screening and targets patients with VTE, pregnancy complications, or family history, addressing accurate detection to guide prophylaxis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing thromboembolic events. Its whole blood-based approach ensures reliable mutation detection.
Other Names: Factor V Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: FVL testing standard; in India, used in VTE clinics.
Purpose: The test assesses 3 parameters including Factor V Leiden mutation to guide thrombophilia screening, detect genetic risk, inform prophylaxis.
Test Parameters: 1. Factor V Leiden Mutation, 2. Genetic Profile, 3. Thrombophilia Risk.
Pretest Condition: No fasting required; patients should report VTE, pregnancy loss, or family history.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on thrombosis episodes, pregnancy outcomes, OCP use.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected thrombophilia including VTE, benefits of screening, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive FVL indicates increased VTE risk, necessitating specialist input. Negative may require follow-up if history strong.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: Protein C/S, antiphospholipid antibodies for confirmation.
Test Limitations: Limited to FVL; comprehensive approach required.
References: Indian Journal of Hematology 2024, Thrombophilia Studies India 2023.
